AllStripes Enters Partnership with Penn’s Orphan Disease Center

Rare Daily Staff

AllStripes, a healthcare technology company dedicated to accelerating drug research for patients with rare diseases, said it entered into a partnership with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania to advance the development of gene therapies in Lesch-Nyhan disease and a second rare disease to be named soon.

AllStripes has developed a novel technology platform that generates clinical evidence to accelerate rare disease research and drug development, as well as a patient application that allows patients and families to participate in research from home.

Through this partnership, the Orphan Disease Center will leverage AllStripes’ platform to launch real-world evidence studies aimed at advancing clinical understanding of these diseases through natural history, disease progression, and disease severity, with outcomes including quality of life, activities of daily living, health resource utilization and other clinical outcomes.

“When we come together and learn from each other’s experiences we can push for better treatments across all rare conditions,” said Nancy Yu, co-founder and chief executive officer of AllStripes. “This year we have already expanded from 12 diseases to 20, and today we are thrilled to offer people living with Lesch-Nyhan disease a streamlined way to access their medical records and participate in research online. Penn Medicine’s Orphan Disease Center is an esteemed leader in gene therapy and rare disease research, and we are proud to have them as a partner as we create a research resource for the rare disease community that enables the development of novel treatments.”

Photo: Nancy Yu, co-founder and CEO of AllStripes